Also known as: Methylprednisolone
A case series of three Erdheim-Chester disease patients demonstrates the disease's diagnostic challenges, with one patient improving on targeted BRAF inhibition while two others died within a year. The rare histiocytosis often presents with multisystem involvement, delaying diagnosis.
Recent market reports forecast significant growth in the progressive pulmonary fibrosis market, set to reach $2.7 billion by 2035, and the global asthma and COPD drugs market, projected to hit US$ 82.2 billion by 2036. The Asia Pacific pharma 4.0 market is also expanding rapidly, driven by digital technologies like AI and IoT.
Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.
Duchenne muscular dystrophy care is shifting toward broader multidisciplinary management and closer attention to early pathology, biomarkers, and treatment timing. Clinicians described an expanding treatment landscape and identified neurology, cardiology, pulmonary, and endocrinology as core priorities.
The multiple myeloma treatment landscape is rapidly expanding with over 75 companies developing 80+ pipeline therapies, while clinicians navigate evolving questions about transplant timing, quadruplet regimens, and minimal residual disease testing in newly diagnosed patients.
Five intra-articular gene therapy platforms for knee osteoarthritis are in human trials in the US, while India prepares regulatory guidelines for mRNA, gene and cell therapies to accelerate innovation.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
New research demonstrates that dexamethasone effectively ameliorates cytokine-release syndrome in CAR T-cell therapy for multiple myeloma while maintaining or enhancing anti-tumor activity and increasing CAR T-cell levels.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07565844 |
Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia |
RECRUITING | NA |
| NCT07340723 |
Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) |
RECRUITING | PHASE2 |
| NCT07297914 |
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT06585774 |
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease |
RECRUITING | PHASE3 |
| NCT06521762 |
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis |
WITHDRAWN | PHASE2 |
| NCT06388564 |
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06141161 |
Assessment of Bronchial Asthma Among Patients Attending Sohag University Hospital |
RECRUITING | |
| NCT06060301 |
Topical Sulfasalazine and Oral Lichen Planus |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06019507 |
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05899725 |
The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia |
RECRUITING | NA |
